Tuberculosis: vaccines in the pipeline

References

• Fine P. Stopping routine vaccination for tuberculosis in schools. BMJ331, 647–648 (2005).
   PubMedGoogle Scholar
• Nunn P, Williams B, Floyd K, Dye C, Elzinga G, Raviglione M. Tuberculosis control in the era of HIV. Nat. Rev. Immunol.5, 819–826 (2005).
   PubMed Web of Science ®Google Scholar
• Cobelens FG, van Deutekom H, Draayer-Jansen IW et al. Risk of infection with Mycobacterium tuberculosis in travellers to areas of high tuberculosis endemicity. Lancet356, 461–465 (2000).
   PubMed Web of Science ®Google Scholar
• Houston S. Tuberculosis risk and prevention in travelers – what about BCG? J. Travel Med.4, 76–82 (1997).
   PubMedGoogle Scholar
• Jung P, Banks RH. Tuberculosis risk in US Peace Corps Volunteers, 1996 to 2005. J. Travel Med.15, 87–94 (2008).
   PubMedGoogle Scholar
• Brosch R, Vincent V. Cutting-edge science and the future of tuberculosis control. Bull. World Health Organ.85, 410–412 (2007).
   PubMedGoogle Scholar
• Mitsuyama M, McMurray DN. Tuberculosis: vaccine and drug development. Tuberculosis (Edinb.)87(Suppl. 1), S10–S13 (2007).
   Google Scholar
• Skeiky YA, Sadoff JC. Advances in tuberculosis vaccine strategies. Nat. Rev. Microbiol.4, 469–476 (2006).
   PubMed Web of Science ®Google Scholar
• Andersen P. Tuberculosis vaccines – an update. Nat. Rev. Microbiol.5, 484–487 (2007).
   PubMed Web of Science ®Google Scholar
• Reed S, Lobet Y. Tuberculosis vaccine development; from mouse to man. Microbes Infect.7, 922–931 (2005).
   PubMed Web of Science ®Google Scholar
• Kaufmann SH. The contribution of immunology to the rational design of novel antibacterial vaccines. Nat. Rev. Microbiol.5, 491–504 (2007).
   PubMed Web of Science ®Google Scholar
• Beveridge NE, Price DA, Casazza JP et al. Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations. Eur. J. Immunol.37, 3089–3100 (2007).
   PubMed Web of Science ®Google Scholar
• Majlessi L, Simsova M, Jarvis Z et al. An increase in antimycobacterial Th1-cell responses by prime–boost protocols of immunization does not enhance protection against tuberculosis. Infect. Immun.74, 2128–2137 (2006).
   PubMed Web of Science ®Google Scholar
• Brennan MJ, Fruth U, Milstien J, Tiernan R, de Andrade Nishioka S, Chocarro L. Development of new tuberculosis vaccines: a global perspective on regulatory issues. PLoS Med.4, e252 (2007).
   PubMed Web of Science ®Google Scholar
• Sadoff JC, Hone D. The role of “go no-go” decisions in TB vaccine development. Microbes Infect.7, 899–904 (2005).
   PubMedGoogle Scholar
• Williams A, Hatch GJ, Clark SO et al. Evaluation of vaccines in the EU TB vaccine cluster using a guinea pig aerosol infection model of tuberculosis. Tuberculosis (Edinb.)85, 29–38 (2005).
   PubMed Web of Science ®Google Scholar
• Girard MP, Fruth U, Kieny MP. A review of vaccine research and development: tuberculosis. Vaccine23, 5725–5731 (2005).
   PubMed Web of Science ®Google Scholar
• Young D, Dye C. The development and impact of tuberculosis vaccines. Cell124, 683–687 (2006).
   PubMed Web of Science ®Google Scholar
• Gupta UD, Katoch VM, McMurray DN. Current status of TB vaccines. Vaccine25, 3742–3751 (2007).
   PubMed Web of Science ®Google Scholar
• Roth AE, Stensballe LG, Garly ML, Aaby P. Beneficial non-targeted effects of BCG – ethical implications for the coming introduction of new TB vaccines. Tuberculosis (Edinb.)86, 397–403 (2006).
   PubMed Web of Science ®Google Scholar
• McShane H, Hill A. Prime–boost immunisation strategies for tuberculosis. Microbes Infect.7, 962–967 (2005).
   PubMed Web of Science ®Google Scholar
• Xing Z, Carters TJ. Heterologous boost vaccines for bacillus Calmette–Guerin prime immunization against tuberculosis. Expert Rev. Vaccines6(4), 539–546 (2007).
   PubMed Web of Science ®Google Scholar
• Haile M, Hamasur B, Jaxmar T et al. Nasal boost with adjuvanted heat-killed BCG or arabinomannan-protein conjugate improves primary BCG-induced protection in C57BL/6 mice. Tuberculosis (Edinb.)85, 107–114 (2005).
   PubMed Web of Science ®Google Scholar
• Rodrigues LC, Pereira SM, Cunha SS et al. Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG–REVAC cluster-randomised trial. Lancet366, 1290–1295 (2005).
   PubMed Web of Science ®Google Scholar
• Dietrich J, Andersen C, Rappuoli R, Doherty TM, Jensen CG, Andersen P. Mucosal administration of Ag85B–ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette–Guerin immunity. J. Immunol.177, 6353–6360 (2006).
   PubMed Web of Science ®Google Scholar
• Andersen CS, Dietrich J, Agger EM, Lycke NY, Lovgren K, Andersen P. The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis. Infect. Immun.75, 408–416 (2007).
   PubMed Web of Science ®Google Scholar
• Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic S. Enhancing the protective efficacy of Mycobacterium bovis BCG vaccination against tuberculosis by boosting with the Mycobacterium tuberculosis major secretory protein. Infect. Immun.73, 4676–4683 (2005).
   PubMed Web of Science ®Google Scholar
• Romano M, D’Souza S, Adnet PY et al. Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv. Vaccine24, 3353–3364 (2006).
   PubMed Web of Science ®Google Scholar
• Santosuosso M, McCormick S, Zhang X, Zganiacz A, Xing Z. Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis. Infect. Immun.74, 4634–4643 (2006).
   PubMed Web of Science ®Google Scholar
• Pathan AA, Sander CR, Fletcher HA et al. Boosting BCG with recombinant modified vaccinia Ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials. PLoS ONE2, e1052 (2007).
   PubMedGoogle Scholar
• Behr MA, Small PM. Has BCG attenuated to impotence? Nature389, 133–134 (1997).
   PubMed Web of Science ®Google Scholar
• Hernandez-Pando R, Castanon M, Espitia C, Lopez-Vidal Y. Recombinant BCG vaccine candidates. Curr. Mol. Med.7, 365–372 (2007).
   PubMed Web of Science ®Google Scholar
• Nasser Eddine A, Kaufmann SH. Improved protection by recombinant BCG. Microbes Infect.7, 939–946 (2005).
   PubMedGoogle Scholar
• Castanon-Arreola M, Lopez-Vidal Y, Espitia-Pinzon C, Hernandez-Pando R. A new vaccine against tuberculosis shows greater protection in a mouse model with progressive pulmonary tuberculosis. Tuberculosis (Edinb.)85, 115–126 (2005).
   PubMedGoogle Scholar
• Sugawara I, Li Z, Sun L, Udagawa T, Taniyama T. Recombinant BCG Tokyo (Ag85A) protects cynomolgus monkeys (Macaca fascicularis) infected with H37Rv Mycobacterium tuberculosis. Tuberculosis (Edinb.)87, 518–525 (2007).
   PubMed Web of Science ®Google Scholar
• Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic S. A novel live recombinant mycobacterial vaccine against bovine tuberculosis more potent than BCG. Vaccine24, 1593–1600 (2006).
   PubMed Web of Science ®Google Scholar
• Ryan AA, Spratt JM, Britton WJ, Triccas JA. Secretion of functional monocyte chemotactic protein 3 by recombinant Mycobacterium bovis BCG attenuates vaccine virulence and maintains protective efficacy against M. tuberculosis infection. Infect. Immun.75, 523–526 (2007).
   PubMed Web of Science ®Google Scholar
• Aldwell FE, Cross ML, Fitzpatrick CE, Lambeth MR, de Lisle GW, Buddle BM. Oral delivery of lipid-encapsulated Mycobacterium bovis BCG extends survival of the bacillus in vivo and induces a long-term protective immune response against tuberculosis. Vaccine24, 2071–2078 (2006).
   PubMed Web of Science ®Google Scholar
• Grode L, Seiler P, Baumann S et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette–Guerin mutants that secrete listeriolysin. J. Clin. Invest.115, 2472–2479 (2005).
   PubMed Web of Science ®Google Scholar
• Mahairas GG, Sabo PJ, Hickey MJ, Singh DC, Stover CK. Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. J. Bacteriol.178, 1274–1282 (1996).
   PubMed Web of Science ®Google Scholar
• Behr MA, Wilson MA, Gill WP et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science284, 1520–1523 (1999).
   PubMed Web of Science ®Google Scholar
• Sambandamurthy VK, Jacobs WR Jr. Live attenuated mutants of Mycobacterium tuberculosis as candidate vaccines against tuberculosis. Microbes Infect.7, 955–961 (2005).
   PubMed Web of Science ®Google Scholar
• Hernandez Pando R, Aguilar LD, Infante E et al. The use of mutant mycobacteria as new vaccines to prevent tuberculosis. Tuberculosis (Edinb.)86, 203–210 (2006).
   PubMed Web of Science ®Google Scholar
• Sambandamurthy VK, Derrick SC, Hsu T et al.Mycobacterium tuberculosis δRD1 DeltapanCD: a safe and limited replicating mutant strain that protects immunocompetent and immunocompromised mice against experimental tuberculosis. Vaccine24, 6309–6320 (2006).
   PubMed Web of Science ®Google Scholar
• Waters WR, Palmer MV, Nonnecke BJ et al. Failure of a Mycobacterium tuberculosis DRD1 DpanCD double deletion mutant in a neonatal calf aerosol M. bovis challenge model: comparisons to responses elicited by M. bovis bacille Calmette Guerin. Vaccine25, 7832–7840 (2007).
   PubMedGoogle Scholar
• Hinchey J, Lee S, Jeon BY et al. Enhanced priming of adaptive immunity by a proapoptotic mutant of Mycobacterium tuberculosis. J. Clin. Invest.117, 2279–2288 (2007).
   PubMed Web of Science ®Google Scholar
• Martin C, Williams A, Hernandez-Pando R et al. The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs. Vaccine24, 3408–3419 (2006).
   PubMed Web of Science ®Google Scholar
• Lowrie DB. DNA vaccines for therapy of tuberculosis: where are we now? Vaccine24, 1983–1989 (2006).
   PubMed Web of Science ®Google Scholar
• Triccas JA, Shklovskaya E, Spratt J et al. Effects of DNA- and Mycobacterium bovis BCG-based delivery of the Flt3 ligand on protective immunity to Mycobacterium tuberculosis. Infect. Immun.75, 5368–5375 (2007).
   PubMed Web of Science ®Google Scholar
• McMurry JA, Kimball S, Lee JH et al. Epitope-driven TB vaccine development: a streamlined approach using immuno-informatics, ELISpot assays, and HLA transgenic mice. Curr. Mol. Med.7, 351–368 (2007).
   PubMed Web of Science ®Google Scholar
• Derrick SC, Yang AL, Morris SL. A polyvalent DNA vaccine expressing an ESAT6–Ag85B fusion protein protects mice against a primary infection with Mycobacterium tuberculosis and boosts BCG-induced protective immunity. Vaccine23, 780–788 (2004).
   PubMed Web of Science ®Google Scholar
• Wu Y, Woodworth JS, Shin DS, Morris S, Behar SM. Vaccine-elicited 10-kilodalton culture filtrate protein-specific CD8+ T cells are sufficient to mediate protection against Mycobacterium tuberculosis infection. Infect. Immun.76, 2249–2255 (2008).
   PubMed Web of Science ®Google Scholar
• Sugawara I, Udagawa T, Taniyama T. Protective efficacy of recombinant (Ag85A) BCG Tokyo with Ag85A peptide boosting against Mycobacterium tuberculosis-infected guinea pigs in comparison with that of DNA vaccine encoding Ag85A. Tuberculosis (Edinb.)87, 94–101 (2007).
   PubMedGoogle Scholar
• Vipond J, Vipond R, Allen-Vercoe E et al. Selection of novel TB vaccine candidates and their evaluation as DNA vaccines against aerosol challenge. Vaccine24, 6340–6350 (2006).
   PubMedGoogle Scholar
• Okada M, Kita Y, Nakajima T et al. Evaluation of a novel vaccine (HVJ-liposome/HSP65 DNA+IL-12 DNA) against tuberculosis using the cynomolgus monkey model of TB. Vaccine 25, 2990–2993 (2007).
   PubMed Web of Science ®Google Scholar
• Maue AC, Waters WR, Palmer MV et al. An ESAT-6:CFP10 DNA vaccine administered in conjunction with Mycobacterium bovis BCG confers protection to cattle challenged with virulent M. bovis. Vaccine25, 4735–4746 (2007).
   PubMedGoogle Scholar
• Li H, Li R, Zhong S et al. The immunogenicity and protective efficacy of Mtb8.4/hIL-12 chimeric gene vaccine. Vaccine24, 1315–1323 (2006).
   PubMedGoogle Scholar
• Zhang X, Divangahi M, Ngai P et al. Intramuscular immunization with a monogenic plasmid DNA tuberculosis vaccine: enhanced immunogenicity by electroporation and co-expression of GM-CSF transgene. Vaccine25, 1342–1352 (2007).
   PubMed Web of Science ®Google Scholar
• Yoshida S, Tanaka T, Kita Y et al. DNA vaccine using hemagglutinating virus of Japan-liposome encapsulating combination encoding mycobacterial heat shock protein 65 and interleukin-12 confers protection against Mycobacterium tuberculosis by T cell activation. Vaccine24, 1191–1204 (2006).
   PubMed Web of Science ®Google Scholar
• Chang-Hong S, Xiao-Wu W, Hai Z, Ting-Fen Z, Li-Mei W, Zhi-Kai X. Immune responses and protective efficacy of the gene vaccine expressing Ag85B and ESAT6 fusion protein from Mycobacterium tuberculosis. DNA Cell Biol.27(4), 199–207 (2008).
   PubMed Web of Science ®Google Scholar
• Fan X, Gao Q, Fu R. DNA vaccine encoding ESAT-6 enhances the protective efficacy of BCG against Mycobacterium tuberculosis infection in mice. Scand. J. Immunol.66, 523–528 (2007).
   PubMedGoogle Scholar
• Yu DH, Li M, Hu XD, Cai H. A combined DNA vaccine enhances protective immunity against Mycobacterium tuberculosis and Brucella abortus in the presence of an IL-12 expression vector. Vaccine25, 6744–6754 (2007).
   PubMed Web of Science ®Google Scholar
• Andersen P, Doherty TM. TB subunit vaccines – putting the pieces together. Microbes Infect.7, 911–921 (2005).
   PubMed Web of Science ®Google Scholar
• Doherty TM, Dietrich J, Billeskov R. Tuberculosis subunit vaccines: from basic science to clinical testing. Expert Opin. Biol. Ther.7, 1539–1549 (2007).
   PubMed Web of Science ®Google Scholar
• Walker KB, Keeble J, Colaco C. Mycobacterial heat shock proteins as vaccines – a model of facilitated antigen presentation. Curr. Mol. Med.7, 339–350 (2007).
   PubMed Web of Science ®Google Scholar
• Sable SB, Plikaytis BB, Shinnick TM. Tuberculosis subunit vaccine development: impact of physicochemical properties of mycobacterial test antigens. Vaccine25, 1553–1566 (2007).
   PubMedGoogle Scholar
• Campuzano J, Aguilar D, Arriaga K et al. The PGRS domain of Mycobacterium tuberculosis PE_PGRS Rv1759c antigen is an efficient subunit vaccine to prevent reactivation in a murine model of chronic tuberculosis. Vaccine25, 3722–3729 (2007).
   PubMed Web of Science ®Google Scholar
• Rigano MM, Dreitz S, Kipnis AP, Izzo AA, Walmsley AM. Oral immunogenicity of a plant-made, subunit, tuberculosis vaccine. Vaccine24, 691–695 (2006).
   PubMed Web of Science ®Google Scholar
• Hovav AH, Bercovier H. Pseudo-rationale design of efficient TB vaccines: lesson from the mycobacterial 27-kDa lipoprotein. Tuberculosis (Edinb.)86, 225–235 (2006).
   PubMed Web of Science ®Google Scholar
• Wang B, Henao-Tamayo M, Harton M et al. A Toll-like receptor-2-directed fusion protein vaccine against tuberculosis. Clin. Vaccine Immunol.14, 902–906 (2007).
   PubMedGoogle Scholar
• Jeon BY, Kim HJ, Kim SC et al. Protection of mice against Mycobacterium tuberculosis infection by immunization with aqueous fraction of Triton X-100-soluble cell wall proteins. Scand. J. Immunol.67, 18–23 (2008).
   PubMedGoogle Scholar
• Agger EM, Rosenkrands I, Olsen AW et al. Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31. Vaccine24, 5452–5460 (2006).
   PubMed Web of Science ®Google Scholar
• Wong YL, Sampson S, Germishuizen WA et al. Drying a tuberculosis vaccine without freezing. Proc. Natl Acad. Sci. USA104, 2591–2595 (2007).
   PubMed Web of Science ®Google Scholar